AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7192075 — intervention group
Group type: EXPERIMENTAL
Intervention: Children suspected of being allergic to egg
Number of subjects: 126
Study 7192075 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with both a present history of food allergy and a positive skin test for that allergen
Number of subjects: 126
Study 7192075 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive challenges
Number of subjects: 126
Study 7192075 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of food allergy in children sensitive to food allergens
Number of subjects: 126
Study 31610633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough
Number of subjects: 1000
Study 31610633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinitis
Number of subjects: 1000
Study 28444936 — intervention group
Group type: EXPERIMENTAL
Intervention: HI‐ECC+BFR
Number of subjects: 9
Study 28444936 — intervention group
Group type: COMPARATOR
Intervention: HI‐ECC
Number of subjects: 9
Study 27376594 — intervention group
Group type: EXPERIMENTAL
Intervention: Community cash transfers (generasi)
Number of subjects: 26000
Study 27376594 — intervention group
Group type: EXPERIMENTAL
Intervention: Household cash transfers (PKH)
Number of subjects: 26000
Study 24411134 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-NGF (CERE-110)
Number of subjects: 10
Study 23495555 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinpoint guidance
Number of subjects: 118
Study 23495555 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf gauge
Number of subjects: 118
Study 23495555 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 20810509 — intervention group
Group type: EXPERIMENTAL
Intervention: IA‐BoNT/A
Number of subjects: 49
Study 20810509 — intervention group
Group type: COMPARATOR
Intervention: IA‐placebo
Number of subjects: 49
Study 17202154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity levels
Number of subjects: 19574
Study 17202154 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health measures
Number of subjects: 19574
Study 16034308 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus nIFN‐alpha
Number of subjects: 108
Study 16034308 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD plus nIFN‐alpha
Number of subjects: 108
Study 16034308 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus rIFN‐alpha2b
Number of subjects: 108
Study 16034308 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD plus rIFN‐alpha2b
Number of subjects: 108
Study 16034308 — intervention group
Group type: COMPARATOR
Intervention: BOLD
Number of subjects: 108
Study 16034308 — intervention group
Group type: COMPARATOR
Intervention: All arms
Number of subjects: 108
Study 12063096 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs) cited in guidelines
Number of subjects: 191
Study 12063096 — intervention group
Group type: EXPERIMENTAL
Intervention: References of guidelines
Number of subjects: 191
Study 12063096 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines with <2 RCTs cited
Number of subjects: 191
Study 9866536 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sampling from peripheral intravenous infusion lines
Number of subjects: 55
Study 9866536 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral saline locks
Number of subjects: 55
Study 9866536 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venipuncture
Number of subjects: 55
Study 7715904 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron i.v. + placebo p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Number of subjects: 488
Study 7715904 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo i.v. + 8 mg ondansetron p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Number of subjects: 488
Study 7715904 — intervention group
Group type: COMPARATOR
Intervention: 3 mg granisetron i.v. + placebo p.o. before chemotherapy + placebo p.o. b.d. until day 5
Number of subjects: 488
Study 7715904 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. and p.o. ondansetron
Number of subjects: 488
Study 7715904 — intervention group
Group type: EXPERIMENTAL
Intervention: all-p.o. ondansetron regimen
Number of subjects: 488
Study 7715904 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. + ondansetron group
Number of subjects: 488
Study 2462067 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone‐releasing hormone agonist buserelin
Number of subjects: 12
Study 2462067 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogen cyproterone acetate
Number of subjects: 12
Study 880971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg b.i.d. for 3 weeks and 200 mg b.i.d. for 3 weeks)
Number of subjects: 10
Study 880971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 10
Study 31994616 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS) technique
Number of subjects: 90
Study 31994616 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (P) technique
Number of subjects: 90
Study 31994616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline + physiotherapy (HSP) technique
Number of subjects: 90
Study 31994616 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (HS) technique
Number of subjects: 90
Study 30300021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined laser with topical photo‐enhancer gel
Number of subjects: 20
Study 30300021 — intervention group
Group type: COMPARATOR
Intervention: Solo laser treatment
Number of subjects: 20
Study 29029097 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU/d Vitamin D3
Number of subjects: 685
Study 29029097 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d Vitamin D3
Number of subjects: 685
Study 29029097 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d Vitamin D3
Number of subjects: 685
Study 29029097 — intervention group
Group type: COMPARATOR
Intervention: Control (lower doses)
Number of subjects: 685
Study 25892658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (.08 mg/kg)
Number of subjects: 55
Study 25892658 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 55
Study 23356494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iloprost after liver transplantation
Number of subjects: 365
Study 23356494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 21904779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (0.3 mg/kg)
Number of subjects: 60
Study 21904779 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg)
Number of subjects: 60
Study 21904779 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 18673303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT) - 4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
Number of subjects: 54
Study 18673303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 54
Study 18673303 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary Treatment Group (MTG) - exercise, dietary and psychological advice, twice a month for 12 months
Number of subjects: 54
Study 18673303 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary Treatment Group (MTG)
Number of subjects: 54
Study 16805719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 16805719 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone
Number of subjects: 0
Study 15223085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg QD (increased to 200 mg QD after 1 week, with further increases allowed up to 400 mg QD)
Number of subjects: 246
Study 15223085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 15223085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER
Number of subjects: 246
Study 11421512 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerbreathe training
Number of subjects: 12
Study 11421512 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 12
Study 9292645 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine devices (IUDs)
Number of subjects: 1337
Study 8417077 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning group (2,500 patients)
Number of subjects: 4006
Study 8417077 — intervention group
Group type: EXPERIMENTAL
Intervention: Model derived from learning group
Number of subjects: 4006
Study 3018602 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus hydrochlorothiazide
Number of subjects: 75
Study 3018602 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (STT)
Number of subjects: 75
Study 30519976 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner‐led interprofessional medication assessment
Number of subjects: 512
Study 30519976 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 512
Study 28349727 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine group (6.4 g day‐1 of β‐alanine)
Number of subjects: 27
Study 28349727 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (6.4 g day‐1 of dextrose)
Number of subjects: 27
Study 25449350 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management of 33 °C (TTM33)
Number of subjects: 22
Study 25449350 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management of 36 °C (TTM36)
Number of subjects: 22
Study 23065656 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (500 mg daily for 6 months)
Number of subjects: 40
Study 23065656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22016344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management intervention for 6 weeks post-discharge, involving over 50 different nursing interventions (2-15 per person) targeting physical, emotional, psychological impairments, role participation restrictions, and health perception.
Number of subjects: 190
Study 22016344 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 190
Study 18840101 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene plexus block
Number of subjects: 26
Study 18840101 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (Control)
Number of subjects: 26
Study 17153886 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with standardized P sylvestris pollen extract
Number of subjects: 35
Study 17153886 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 35
Study 14969156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 15 mg in slow-release form (N-15)
Number of subjects: 15
Study 10711552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel, 90 mg
Number of subjects: 14
Study 10711552 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) progesterone, 50 mg
Number of subjects: 14
Study 8872685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane at MAC 0.5, 1.0, and 1.5
Number of subjects: 20
Study 8872685 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane at MAC 0.5, 1.0, and 1.5
Number of subjects: 20
Study 1739798 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minute appointments
Number of subjects: 16
Study 1739798 — intervention group
Group type: COMPARATOR
Intervention: Normal rate appointments (median six minutes per patient)
Number of subjects: 16
Study 6645520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive program
Number of subjects: 0
Study 6645520 — intervention group
Group type: EXPERIMENTAL
Intervention: Values-clarification program
Number of subjects: 0
Study 6645520 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making program
Number of subjects: 0
Study 31187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting diathermy skin incision
Number of subjects: 64
Study 31187749 — intervention group
Group type: COMPARATOR
Intervention: Scalpel skin incision
Number of subjects: 64
Study 28619005 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (Group A)
Number of subjects: 36
Study 28619005 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral feed (Group B)
Number of subjects: 36
Study 25494870 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon training
Number of subjects: 16
Study 25494870 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 23294143 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing L. reuteri (ATCC55730 and ATCC PTA5289) taken twice a day
Number of subjects: 18
Study 23294143 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges taken twice a day
Number of subjects: 18
Study 21680771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 38
Study 21680771 — intervention group
Group type: COMPARATOR
Intervention: Exercise control (bicycle endurance and stretching exercises)
Number of subjects: 38
Study 21680771 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control (usual medical care)
Number of subjects: 38
Study 19623046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia risk score
Number of subjects: 1856
Study 19623046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation duration
Number of subjects: 1856
Study 19623046 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration and discrimination tests
Number of subjects: 1856
Study 16944194 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina platensis
Number of subjects: 16
Study 14747691 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea drinking
Number of subjects: 0
Study 14747691 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet
Number of subjects: 0
Study 14747691 — intervention group
Group type: COMPARATOR
Intervention: Free living diet
Number of subjects: 0
Study 11240881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.04 mg.kg‐1 (1 mg.m‐2)
Number of subjects: 131
Study 11240881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg.kg‐1 (2.5 mg.m‐2)
Number of subjects: 131
Study 11240881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.2 mg.kg‐1 (5 mg.m‐2)
Number of subjects: 131
Study 11240881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 11240881 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Ondansetron (all doses)
Number of subjects: 131
Study 8051642 — intervention group
Group type: EXPERIMENTAL
Intervention: GpA (scrubbing the operative site for ten minutes with an antiseptic)
Number of subjects: 135
Study 8051642 — intervention group
Group type: COMPARATOR
Intervention: GpB (simplified method where antiseptic was painted onto the operation site)
Number of subjects: 135
Study 3555055 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin (500 mg)
Number of subjects: 40
Study 3555055 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day ciprofloxacin (500 mg twice daily)
Number of subjects: 40
Study 3555055 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day trimethoprim-sulfamethoxazole (160 mg and 800 mg, respectively, twice daily)
Number of subjects: 40
Study 31707100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary choline intake (energy-adjusted)
Number of subjects: 1981
Study 31707100 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine intake
Number of subjects: 1981
Study 31707100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelin intake
Number of subjects: 1981
Study 29643158 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced transtheoretical model of behaviour change in conjunction with physiotherapy
Number of subjects: 220
Study 29643158 — intervention group
Group type: COMPARATOR
Intervention: Standard care (physiotherapy)
Number of subjects: 220
Study 26372728 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 83
Study 26372728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 24991787 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of statins
Number of subjects: 64
Study 24991787 — intervention group
Group type: COMPARATOR
Intervention: Statin-free group
Number of subjects: 64
Study 23690531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Insulin (added to metformin 1,000-2,000 mg/day)
Number of subjects: 5000
Study 20300080 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF) controlled feeding phase for 4 weeks
Number of subjects: 16
Study 18836692 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ascorbate with vitamin C metabolites
Number of subjects: 15
Study 18836692 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C alone
Number of subjects: 15
Study 18836692 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ascorbate with vitamin C metabolites (two formulations)
Number of subjects: 15
Study 18836692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16415712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (CMI) 150 mg on day 1 and 200 mg on day 2, followed by oral CMI starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Number of subjects: 34
Study 16415712 — intervention group
Group type: COMPARATOR
Intervention: Oral clomipramine (CMI) starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Number of subjects: 34
Study 15314994 — intervention group
Group type: EXPERIMENTAL
Intervention: Methizole (thiamazole)
Number of subjects: 144
Study 15314994 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine (131 I)
Number of subjects: 144
Study 15314994 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative procedures
Number of subjects: 144
Study 10653054 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 12 microg + oxitropium bromide 600 microg
Number of subjects: 20
Study 10653054 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 24 microg + oxitropium bromide 600 microg
Number of subjects: 20
Study 10653054 — intervention group
Group type: COMPARATOR
Intervention: formoterol 12 microg
Number of subjects: 20
Study 10653054 — intervention group
Group type: COMPARATOR
Intervention: formoterol 24 microg
Number of subjects: 20
Study 10653054 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo + oxitropium bromide 600 microg
Number of subjects: 20
Study 10653054 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 20
Study 8957981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy logic control of mechanical ventilation
Number of subjects: 30
Study 8957981 — intervention group
Group type: COMPARATOR
Intervention: Manual ventilation control
Number of subjects: 30
Study 8308942 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 3161529 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam; repeated doses
Number of subjects: 0
Study 3161529 — intervention group
Group type: COMPARATOR
Intervention: Diazepam; similar doses given with the same frequency
Number of subjects: 0
Study 31104282 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic Limb (BPL) 70 cm
Number of subjects: 506
Study 31104282 — intervention group
Group type: COMPARATOR
Intervention: Biliopancreatic Limb (BPL) 120 cm
Number of subjects: 506
Study 28474984 — intervention group
Group type: EXPERIMENTAL
Intervention: CO inhalation (carboxyhemoglobin 22%)
Number of subjects: 12
Study 28474984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27101726 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MECC)
Number of subjects: 200
Study 27101726 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 200
Study 24916371 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive couple‐ and parenting‐enhancement program (ProSAAF)
Number of subjects: 331
Study 24916371 — intervention group
Group type: COMPARATOR
Intervention: Information‐only control condition (self‐help materials)
Number of subjects: 331
Study 22918898 — intervention group
Group type: EXPERIMENTAL
Intervention: Health & Safety Association (HSA) consultation
Number of subjects: 2153
Study 22918898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministry of Labour (MOL) inspection
Number of subjects: 2153
Study 22918898 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 2153
Study 21262673 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted inactivated fungal vaccine
Number of subjects: 89
Study 21262673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 18853114 — intervention group
Group type: EXPERIMENTAL
Intervention: Jisuikang (JSK)
Number of subjects: 84
Study 18853114 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional treatment)
Number of subjects: 84
Study 15734602 — intervention group
Group type: EXPERIMENTAL
Intervention: MENQOL-Intervention questionnaire
Number of subjects: 0
Study 15734602 — intervention group
Group type: EXPERIMENTAL
Intervention: MENQOL and MENQOL-Intervention questionnaires
Number of subjects: 0
Study 12737092 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment (3-month electroencephalographic feedback program providing reinforcement contingent on the production of cortical sensorimotor rhythm (12-15 Hz) and beta activity (15-18 Hz))
Number of subjects: 34
Study 12737092 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (stimulant medication)
Number of subjects: 34
Study 10471981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 30 minutes prior to meal
Number of subjects: 18
Study 10471981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 15 minutes prior to meal
Number of subjects: 18
Study 10471981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 1 minute before meal
Number of subjects: 18